Lifeward CEO Mark Grant departs; interim CEO Josh Hexter and CFO Rami Aviram named

Lifeward Ltd.

CEO Mark Grant steps down as President/CEO and director effective Aug 31, 2026; no cash severance, unvested equity forfeited.
Grant to serve as Senior Advisor via consulting agreement through Sep 30, 2026 for $40,000 fee.
Josh Hexter, Oramed's COO, appointed Interim CEO effective Sep 1, 2026; salary NIS 100,000/month + NIS 5,000 allowance.
Rami Aviram appointed CFO effective Nov 1, 2026; salary NIS 70,000/month + NIS 5,000 allowance, succeeding Almog Adar.
Interim CFO to cover gap between Adar's departure (Sep 30) and Aviram's start; Hexter reduces Oramed duties to ~5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.